Quantification of anti-SARS-CoV-2 spike RBD IgG antibody and SARS-CoV-2 virus

The project is focused on designing and developing a novel point of care analytical device using functional magnetic microparticles that can quantitatively determine the concentration of anti-SARS-CoV-2 antibody and SARS-CoV-2 viruses in human saliva and serum. This approach will allow mass testing in the general population to assess past or current infection. Furthermore, it can guide decision-making regarding the optimal time to deliver subsequent vaccine doses and booster shots. The device will give enough information about immunity grown among the general population due to vaccination or prior infection to the virus. A proper market research will allow deciding the next step of commercialization.

Faculty Supervisor:

Michael Serpe

Student:

Partner:

Springboard Atlantic Inc.

Discipline:

Physics

Sector:

Health and Related Sciences & Technology; COVID-19 related Research and Solutions; Biotechnology

University:

University of Alberta

Program: